Articles tagged "Liver transplantation"

2018 American Transplant Congress
Clinical Application of Mesenchymal Stromal Cells with a Simplified Protocol for ABO Incompatible Liver Transplantation in Severe Hepatic Failure Patients
Y. Zhang,^1,2 J. Zheng,^1,2 J. Cai,^1,2 J. Zhang,^1,2 K. Zeng,^1,2 J. Yao,^1,2 Y. Yang.^1,2
¹Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Guangzhou, Guangdong, China; ²Guangdong Key Laboratory of Liver Disease Research, Key Laboratory of Liver Disease Biotherapy and Translational Medicine of Guangdong Higher Education Institutes, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, .
Objective The purpose of this study was to test the safety and efficacy of mesenchymal stromal cells (MSCs) treatment with a simplified protocol for ABO…
2018 American Transplant Congress
Normothermic Machine Perfusion (NMP) Preservation for Human Liver Transplantation in the Cleveland Clinic
Q. Liu, D. Pezzati, A. Hassan, B. Soliman, P. Grady, S. Maikhor, G. Iuppa, T. Diago Uso, K. Hashimoto, F. Aucejo, M. Fujiki, B. Eghtesad, J. Cywinski, S. Irefin, J. Fung, K. Abu-Elmagd, C. Miller, C. Quintini.
Cleveland Clinic, Cleveland, OH.
NMP is a novel preservation method for liver grafts. We transplanted 15 human livers after NMP to test the safety and feasibility of NMP on…
2018 American Transplant Congress
Serelaxin-Notch1 Signaling Promotes Macrophage M2 Differentiation and Alleviates Hepatocellular Damage in Orthotopic Liver Transplantation: From Mouse-to-Human
S. Kageyama,¹ K. Nakamura,¹ B. Ke,¹ R. Sosa,² E. Reed,² F. Kaldas,¹ R. Busuttil,¹ J. Kupiec-Weglinski.¹
¹Surgery, Liver Transplant, UCLA, Los Angeles, CA; ²Pathology, UCLA, Los Angeles, CA.
Background/Aim: We have documented crucial role of macrophage Notch1 signaling in a mouse warm hepatic ischemia-reperfusion injury (IRI) model. However, its clinical relevance or therapeutic…
2018 American Transplant Congress
Examples of the Observer Effect in Transplantation- Unintended Consequences of Regulation and Selected Outcome Metrics
A. Rana, M. Kueht, N. Galvan, R. Cotton, C. O'Mahony, J. Goss.
Abdominal Transplantation, Baylor College of Medicine, Houston, TX.
Introduction: The influence of an observer on the phenomena being observed is designated as the observer effect. It is our aim to demonstrate that an…
2018 American Transplant Congress
Effect of HLA Antibodies on Graft Survival in Adult Live Donor Liver Transplantation
M. Simpson,¹ M. Akoad,¹ F. Gordon,¹ Y-.L. Cheah,¹ C. Simon,¹ J. Pomposelli,² E. Pomfret.²
¹Transplantation, Lahey Hospital & Medical Center, Burlington, MA; ²Transplantation, University of Colorado Medical Center, Aurora, CO.
The relevance of HLA antibodies in liver transplantation is currently being re-evaluated. While hyperacute rejections are not an issue, antibody effects on long-term outcomes are…
2018 American Transplant Congress
Liver Retransplantation and Renal Failure: The Benefit of Simultaneous Kidney Transplant
J. Berumen,¹ V. Irine,² S. Mita,² S. Gabriel,¹ M. Kristin.¹
¹Department of Surgery, University of California San Diego, San Diego, CA; ²Department of Medicine, University of California San Diego, San Diego, CA.
Liver retransplantation has poor survival compared to primary liver transplant. Renal failure is a proven negative risk factor for survival with retransplant. Our aim was…
2018 American Transplant Congress
Liver Transplant Patients with MELD>50 at Listing Have Poor Waitlist Outcomes and Similar Post Transplant Survival to Status 1A Patients
M. Safwan, R. Schilke, U. Nwagu, K. Collins, M. Rizzari, A. Yoshida, M. Abouljoud, S. Nagai.
Henry Ford Health System, Detroit, MI.
Background: Allocation of liver allografts is prioritized to Status 1A patients over end-stage liver disease patients. We aimed to analyze waitlist and transplant outcomes of…
2018 American Transplant Congress
Donor and Procedural Variability in DCD Liver Transplant: Is It Time to Come to a Consensus?
L. Ruffolo, M. Balceniuk, R. Hernandez Alejandro.
Department of Surgery, University of Rochester Medical Center on Behalf of the IDOL Consortium, Rochester, NY.
Background:Donation after cardiocirculatory death liver transplantation (DCD LT) has re-emerged in part because of insufficient grafts for patients on waiting lists. Unfortunately, DCD LT has…
2018 American Transplant Congress
A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients
G. Burckart,¹ M. Cavaillé-Coll,² A. Duong,³ L. Hothem,⁴ R. Albrecht.²
¹Office of Clinical Pharmacology, Office of Translational Science, CDER, US Food and Drug Administration, Silver Spring, MD; ²Division of Transplant and Opthalmology Products, Office of New Drugs, CDER, US Food and Drug Administration, Silver Spring, MD; ³Tauro University, New York, NY; ⁴University of North Carolina, Chapel Hill, NC.
The development of drugs for organ transplantation spanned the time before and after pediatric regulatory requirements under the Best Pharmaceuticals for Children Act (BPCA) and…
2018 American Transplant Congress
Donor-to-Recipient Weight Ratio is Significantly Associated with Hepatic Artery Thrombosis Following Pediatric Whole Liver Transplantation
S. Kim, G. Ramos-Gonzalez, Z. Labib, H. Kim, K. Vakili.
Surgery, Boston Children's Hospital, Boston, MA.
Background: Hepatic artery thrombosis (HAT) following pediatric liver transplantation is associated with increased morbidity and risk of graft failure. In our clinical practice, we have…